Regeneron and Mammoth Collaborate for CRISPR Gene Editing Therapies Against Multiple Diseases

Shots:

Regeneron and Mammoth signed a collaboration to develop and commercialize in vivo CRISPR-based gene editing therapies by using Regeneron’s AAV and antibody engineering and Mammoth’s ultracompact gene editing systems
Under agreement, Mammoth will receive $100M includes $95M upfront cash and equity, $370M R&D and commercial milestones per target, plus single digits to mid-teens royalties, with an option to receive co-funding and profit-sharing on majority of collaborative initiatives in exchange of milestones and royalties
Regeneron get access to Mammoth’s editing technologies, other than certain excluded targets for 5.5yrs; option to extend access for additional 2yrs upon research extension fee payment; both companies will discover targets

Ref: Regeneron | Image: Regeneron